Whalesbook
Margin Pressure Masks Profit Growth
While Alembic Pharmaceuticals reported a significant 29% year-on-year rise in consolidated net profit to ₹202 crore for the fourth quarter ending March 2026, alongside a 4.4% increase in revenues to ₹1,848 crore, the company's operational performance showed signs of strain. The revenue growth was supported by strong performance in its US formulations segment, which increased 11% to ₹564 crore, and a stable domestic branded business contributing ₹568 crore.
EBITDA Declines and Market Reaction
The company's operational profitability faced significant pressure, with EBITDA declining by 16.2% to ₹228 crore. This led to a notable narrowing of the EBITDA margin to 12.3%, down from 15.4% in the same period last year, indicating that costs or expenses may be rising faster than revenue. Following the announcement, Alembic's stock closed down 0.55% at ₹782.10 on the BSE.
Strategic Entry into US Branded Market
Alembic is making a strategic move into the US branded pharmaceuticals market with the launch of Pivya, an antibiotic for uncomplicated urinary tract infections. This segment represents a significant opportunity, with the US market for such treatments projected to reach USD 4.1 billion by 2035. The company is targeting a niche with limited new product introductions over the past decade.
Navigating US Sector Challenges
The wider Indian pharmaceutical industry faces ongoing challenges in the US, including price erosion and regulatory scrutiny. While domestic and European markets are expected to remain stable, the US remains a critical, albeit competitive, territory for growth. Alembic's strategy aims to diversify its revenue streams and capture higher-value segments.
Valuation Compared to Peers
Alembic Pharmaceuticals' valuation places it in the mid-range among its peers. Its trailing twelve-month P/E ratio is around 24.3-24.5, with a market capitalization of approximately ₹15,400 crore. In comparison, Dr. Reddy's Laboratories trades at a P/E of about 17-25, Sun Pharmaceutical Industries at 35-40, and Cipla at 23-30.
Analyst Views Remain Positive
Analysts generally maintain a positive outlook, with a consensus 'Buy' rating and an average 12-month price target of ₹940-₹970, indicating potential upside. The successful growth of the US branded segment is seen as a key factor for future value creation. Management's focus is on disciplined execution to overcome current margin pressures and navigate the challenging US market.